|
[an error occurred while processing this directive]
Generic Drugs
BNA's Web Watch is prepared by Laura
Gordon-Murnane. Documents and Reports are arranged first by
federal government, state governments, international governments,
and nongovernment organizations. E-mail suggestions for future weekly
topics always welcome.
Federal Government
Center for Drug Evaluation and Research (CDER)
updates regularly New
and Generic Drug Approvals: 1998-2002
Congressional Budget Office
How
Increased Competition from Generic Drugs has Affected Prices and
Returns in the Pharmaceutical Industry (July 1998)
Federal Trade Commission
Study
on Generic Drug Market Entry (July 2002)
Generic
Drug Entry Prior to Patent Expiration (July 2002)
Food and Drug Administration
Pharmaceutical
cGMPs for the 21st Century: A science and risk-based approach to
product quality regulation incorporating an integrated quality systems
approach. (August 2002)
General Accounting Office
Prescription
Drugs: State Monitoring Programs Provide Useful Tool to Reduce Diversion.
GAO-02-634 (May 17, 2002)
Nongovernment Organizations
Blue Cross Blue Shield Association
Prescription
Drug Costs: Federal Regulation of the Industry.
Brand-name
vs. Generic Drug Costs
Business for Affordable Medicine
State
Medicaid Survey
The Center for Responsive Politics
Tracking
the Payback - HEALTH: Generic Drugs
Capitol
Eye – Drug War (May 2002)
Center for Studying Health System Change
Affording
Prescription Drugs: Not Just a Problem for the Elderly Research
report No. 5 (April 2002)
Families USA
Where
Prescription Drug Dollars Go Profiting from Pain: A Report (July
2002)
Generic Pharmaceutical Association
Submission
to FDA Symposium on the Hatch-Waxman Act (January 30, 2002)
Drug
Patent Expiration List
An
Economic Prescription for America Generic Drug Utilization: A Cornerstone
of Health Care Value
The Hudson Institute
Hidden Costs of Generic Drugs (July 2002)
Drug
Patents And The Future (2002)
Kaiser Family Foundation
Federal
Policies Affecting The Cost And Availability of New Pharmaceuticals
(July 2002)
Prescription
Drug Trends: A chartbook update November 2001.(November 2001)
2002
Annual Employer Health Benefits Survey (2002)
Seniors
and Prescription Drugs: An 8-State Survey (July 31, 2002))
The National Institute for Health Care Management Research
Changing
Patterns of Pharmaceutical Innovation A research report
A
Primer: Generic Drugs, Patents and the Pharmaceutical Marketplace.
June 2002
Prescription
Drug Expenditures in 2001: Another Year of Escalating Costs
(Revised May 6, 2002)
The Pharmaceutical Care Network
Trends
in Pharmacy Benefit Management for Commercial Plans Pharmacy Benchmarks
Study for Commercial Plans. (2002)
Pharmacy
Benchmarks Study for Managed Care Clients Medicaid.
The Pharmaceutical Research and Manufacturers of America
White
Paper on Implementation of the Hatch-Waxman Act by the U.S. Food
and Drug Administration (January 18, 2002)
The
Value of Medicines 2001
The
Generic Industry's Claims About Prescription Drug Patents: Setting
the Record Straight (June 13, 2002)
NIHCM’s
Report on Pharmaceutical Innovation: Fact vs. Fiction A Preliminary
Report by PhRMA June 11, 2002
The Schneider Institute for Health Policy
Greater
Use of Generics: A Prescription for Drug Cost Savings by Brandeis
University Grant Ritter, Cindy Thomas, and Stanley S. Wallack
University of Maryland School of Pharmacy And University
of Maryland Center on Drugs and Public Policy
Projection
of Drug Approvals, Patent Expirations, and Generic Entry from 2000
to 2004 by C. Daniel Mullins, Ph.D. Francis Palumbo, Ph.D.,
J.D. Bruce Stuart, Ph.D. (August 2000)
|
